Introduction

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field.

Enanta is developing novel protease, NS5A, polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA.


Enanta Pharmaceuticals is a privately held company with offices in Watertown, MA.

click here for more


Press Releases
April 19, 2012
Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C

April 19, 2012
Abbott Presents Positive Results from Interferon-Free
Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C

April 4, 2012
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL

February 21, 2012
Enanta Enters into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV

Archives